| abstract |
The application describes compounds of the formula (I) which are inhibitors of protein tyrosine phosphatases (PTPases) and in this way they can be used for the treatment of pathological conditions mediated by PTPase activity. The compounds proposed in this invention can also be used as inhibitors of other enzymes containing a phosphotyrosine binding region, such as the SH2 domain. Accordingly, the compounds of formula (I) can be used to prevent and/or treat obesity-related insulin resistance, glucose intolerance, diabetes, hypertension and ischemic diseases of large and small blood vessels, pathological conditions accompanying type 2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipocyte tumors and carcinomas such as liposarcoma, dyslipidemia, and other pathological conditions in which insulin resistance is found. In addition, the compounds proposed in this invention can be used for the treatment and/or prevention of cancer, osteoporosis, neurodegenerative and infectious diseases and diseases involving inflammation, and diseases of the immune system. In the application, compounds of the formula (I) are described, which are inhibitors of protein tyrosine phosphatases (PTPases) and can be used in this way for the treatment of pathological conditions, oposre due to the activity of PTPase. The compounds proposed in this invention can also be used as inhibitors of other enzymes that contain a region that binds phosphotyrosine, such as the SH2 domain. Accordingly, compounds of formula (I) can be used for � |